A long-term survival pattern for breast cancer treated in a single institution

Gokce, Tumay; Karadogan, Ilker; Akcay, Cimen

doi:10.4103/0019-509x.82884

Cited by 2 publications

(1 citation statement)

References 13 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Women diagnosed with BC at <40 years presented a lower survival than those diagnosed at the ages of 40-49 years (median survival: 118 vs. 129 months, HR=0.82, p=0.015). These results match the published data on BC Portuguese women (4-9, 15, 26) suggesting that younger patients might present a more aggressive BC phenotype (22). Patients diagnosed at 65 years and older had a significantly inferior median survival compared to the younger groups (87 months) and had a risk of death of almost threefold higher than that of patients under 40 years at diagnosis, with differences in survival being detected early in the follow-up period.…”

Section: Discussionsupporting

confidence: 90%

Overall Survival of Patients With Locoregional and Metastatic Breast Cancer: Is the Influence of Baseline Characteristics the Same?

et al. 2019

View full text Add to dashboard Cite

Aim: To compare the overall survival (OS) of patients with locoregional and metastatic breast cancer (BC) considering baseline demographic, clinical and contextual characteristics. Materials and Methods: A retrospective analysis of a cancer registry was conducted, using the Kaplan-Meier and Mantel-Cox analyses for the calculation of median OS and cumulative survival. Results: The median OS was 112 months, being longer in patients with locoregional versus those with metastatic BC at diagnosis (115 vs. 31 months, p<0.001). The cumulative survival at 1, 3 and 5 years were 94.9%, 85.6% and 76.5%, respectively. More recent year of diagnosis [hazard ratio (HR)=1.09] and age at diagnosis (≥65 vs. 40 years, HR=2.79) and presence of metastatic disease (HR=5.69) were associated with a shorter OS. The region of residence, morphology and topography of the tumor were also associated with survival in patients with BC. Rurality was only associated with lower survival in patients with metastatic BC. Conclusion: This study identified significant differences in the median OS of patients with locoregional and those with metastatic BC considering their baseline characteristics.Breast cancer (BC) is the most frequent malignant disease in women worldwide (1, 2), in Europe (2, 3) and in Portuguese women (3-9). Survival of patients with BC has expanded over time (10-16), an improvement that can be attributed to the increase in cases being diagnosed early (11,(17)(18)(19)(20), screening actions (11-13, 17, 20), and treatment advances (10-12, 17, 20-22). The survival of patients with BC has also been associated with other factors such as stage (10-14, 17, 20-23) and age at diagnosis (4, 5, 6-12, 14, 15, 16, 21, 24-26), rurality (25, 27), and other prognostic factors (16, 28) such as the histology of the tumor (13,16,28,29) and tumor location (30).To date, few publications have compared the overall survival of patients with locoregional and metastatic BC and correlated it with the patients' baseline characteristics. A study conducted in patients diagnosed with BC in 1990-1999 in 10 European countries identified 5-and 10-year all-cause overall survival rates of 89% and 80%, respectively ( 13). An analysis conducted in the Cote D'Or registry on patients with metastatic BC diagnosed in 2000-2011 showed survival rates at 1 and 2 years of 67.3% and 47.5%, respectively, with a median survival of 22.7 months ( 16). Another publication on this topic reported overall survival of 92.9%, 77.6% and 65.5% at 1, 3 and 5 years, respectively, in Italian women diagnosed in 1979-1981 (24). A further study conducted on Scottish women with non-metastatic BC diagnosed in 1987-1993 showed that the 8-year overall survival decreased with age (12), and another analysis of Turkish women conducted between 1995 and 2008 found a median survival of 120 months, with 90% survival at the 5-year cut-off date ( 22). Additionally, a retrospective study conducted on patients with metastatic BC diagnosed in 1980-2009 in Germany reported a median survival of 85 months, with w...

show abstract

Section: Discussionsupporting

confidence: 90%